Barrou J, Bannier M, Cohen M, Lambaudie E, Gonçalves A, Bertrand P, Buttarelli M, Opinel P, Sterkers N, Tallet A, Zinzindohoué C, Houvenaeghel G
Institut Paoli Calmette, Marseille and CRCM, Aix Marseille University, France.
Institut Paoli Calmette, Marseille, France.
Breast. 2017 Apr;32:37-43. doi: 10.1016/j.breast.2016.12.014. Epub 2016 Dec 26.
Even if neoadjuvant chemotherapy (NACT) and oncoplastic techniques have increased the breast conserving surgery rate, mastectomy is still a standard for multifocal or extensive breast cancers (BC). In the prospect of increasing breast reconstruction, an alternative therapeutic protocol was developed combining NACT with neoadjuvant radiation therapy (NART), followed by mastectomy with immediate breast reconstruction (IBR). The oncological safety of this therapeutic plan still needs further exploration. We assessed pathological complete response (pCR) as a surrogate endpoint for disease free survival.
Between 2010 and 2016, 103 patients undergoing mastectomy after NACT and NART were recruited. After CT and RT were administrated, a completion mastectomy with IBR by latissimus dorsi flap was achieved 6 to 8 weeks later. pCR was defined by the absence of residual invasive disease in both nodes and breast. Histologic response was analyzed for each immunohistochemical subset.
pCR was obtained for 53.4% of the patients. This pCR rate was higher in hormonal receptor negative (HER2 and triple negative) patients when compared to luminal tumours (69.7% vs 45.7%, p=0.023).
The pCR rate found in this study is higher than those published in studies analyzing NACT (12.5%-27.1%). This can be explained by the combination of anthracycline and taxane, the use of trastuzumab when HER2 was overexpressed but also by RT associated to NACT.
Inverting the sequence protocol for BC, requiring both CT and RT, allows more IBR without diminishing pCR and should therefore be considered as an acceptable therapeutic option.
即使新辅助化疗(NACT)和肿瘤整形技术提高了保乳手术率,但对于多灶性或广泛性乳腺癌(BC),乳房切除术仍是标准术式。在增加乳房重建的前景下,制定了一种替代治疗方案,即NACT联合新辅助放疗(NART),随后进行乳房切除术并即刻乳房重建(IBR)。该治疗方案的肿瘤学安全性仍需进一步探索。我们将病理完全缓解(pCR)评估为无病生存的替代终点。
2010年至2016年期间,招募了103例在接受NACT和NART后接受乳房切除术的患者。在进行CT和放疗后,6至8周后通过背阔肌皮瓣完成乳房切除术并进行IBR。pCR定义为淋巴结和乳房均无残留浸润性疾病。对每个免疫组化亚组分析组织学反应。
53.4%的患者获得了pCR。与管腔型肿瘤相比,激素受体阴性(HER2和三阴性)患者的pCR率更高(69.7%对45.7%,p = 0.023)。
本研究中发现的pCR率高于分析NACT的研究中公布的pCR率(12.5%-27.1%)。这可以通过蒽环类药物和紫杉烷的联合使用、HER2过表达时曲妥珠单抗的使用以及与NACT相关的放疗来解释。
颠倒BC的序贯方案,同时进行CT和放疗,可在不降低pCR的情况下实现更多的IBR,因此应被视为一种可接受的治疗选择。